Individuals in this age group should only receive this vaccine as their booster.
So far, existing vaccines have proven effective against prior coronavirus variants, including the delta variant.
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health.
Researchers conducted a study to determine the effect of a national human papillomavirus (HPV) immunization program on the incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia among young women in England.
The October approvals include treatments for acute pain, opioid overdose, dry eye disease, and COVID-19 vaccine for children 5 to 11 years of age.
Until now, the shots were recommended only for certain groups of adults.
CDC Director Rochelle P. Walensky, MD, MPH endorsed the ACIP’s recommendation.
To answer the many questions regarding the roll out, risk and benefits, and timing of COVID-19 vaccine administration in children aged 5 to 11 years, The Clinical Advisor interviewed Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, a pediatric nurse practitioner and owner of Pediatric Nurse Practitioner House Calls.
Small studies have shown that fully vaccinated immunocompromised people account for ~44 percent of breakthrough cases leading to hospitalization.
The panel reviewed safety and efficacy data from a phase 2/3 study that included 2268 participants who received a 2-dose regimen of 10mcg administered 21 days apart.
The update applies to patients who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
Agency will not recommend one vaccine over another but may say it is preferable to use same booster as the vaccine.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
With children back in school and COVID-19 cases persisting, parents may be concerned and seek information about the vaccine. What should they know about the COVID-19 vaccine for children?
NASEM offers recommendations for communicating with parents of young children about COVID-19 vaccines.
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no medical contraindications.
A single booster dose may be administered to individuals 65 years and older and those at high risk of severe disease or exposure to SARS-CoV-2.
New research indicates two doses of the vaccine boosts immunity from 74% to 94%
President Joe Biden uses the full authority of his presidency to push Federal and health care workers to get vaccinated against COVID-19.
Estimates of vaccine effectiveness high for adults 85 years and older, those with chronic medical conditions, and for Hispanic and Black adults.